期刊文献+

中西医结合治疗原发性肝癌黄疸的临床观察 被引量:4

Clinical observation on treating jaundice following primary hepatic carcinoma in the integrative medicine
下载PDF
导出
摘要 目的:探讨中西医结合治疗原发性肝癌黄疸的临床效果。方法:选取2012年2月-2014年2月在我院接受原发性肝癌肝动脉化疗栓塞术后出现黄疸的52例患者作为实验对象,按照治疗方法的不同将其分为对照组和实验组,对照组患者采用单纯西药治疗,实验组在对照组的基础上联用茵陈蒿汤进行治疗,并比较两组患者的临床效果及治疗前后总胆红素变化情况。结果:实验组患者治疗总有效率为84.6%,对照组患者治疗总有效率为57.7%,两组比较差异显著,具有统计学意义(P<0.05);治疗前两组患者总胆红素无明显差异,治疗后实验组患者总胆红素水平显著低于对照组,两组比较差异显著,具有统计学意义(P<0.05)。结论:还原型谷胱甘肽联合茵陈蒿汤在治疗原发性肝癌黄疸方面临床效果显著,值得在临床推广应用。 Objective Clinical effects of the integrative medicine on jaundice following primary hepatic carcinoma wereinvestigated. Methods: 52 patients from February 2012 to February 2014 in our hospital were selected and divided into the control groupand the experimental group according therapies. The control group was given conventional western medicine. The treatment group receivedthe Yinchenhao decoction more. Results: The total efficiency in the experimental group was 84.6%, and in the control group was 57.7%,with obvious difference. Total bilirubin level in the experimental group was significant lower, P〈0.05. Conclusion: Glutathione plus theYinchenhao decoction was obviously effective on jaundice following primary hepatic carcinoma, with high clinical application value.
作者 徐跃峰
机构地区 许昌县人民医院
出处 《中医临床研究》 2016年第10期86-87,共2页 Clinical Journal Of Chinese Medicine
关键词 还原型谷胱甘肽 茵陈蒿汤 原发性肝癌 黄疸 临床效果 Glutathione The Yinchenhao decoction Primary liver cancer Jaundice Clinical effects
  • 相关文献

参考文献4

二级参考文献34

  • 1樊代明,韩国宏,孟祥杰.提高肝癌介入治疗的疗效[J].中华消化杂志,2006,26(5):289-290. 被引量:29
  • 2Marincola FM. Translational medicine:a two-way road. J Transl Med, 2003,1:1.
  • 3Zhou XD, Tang ZY, Yang BH, et al. Hepatocellular carcino- ma: the role of screening. Asian Pac J Cancer Prey, 2000,1: 121-126.
  • 4Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med, 2009,361 : 1437-1447.
  • 5Qian YB, Zhang JB, Wu WZ, et al. P48 is a predictive marker for outcome of postoperative interferon-alpha treatment in pa- tients with hepatitis B virus injection-related hepatocellular carcinoma. Cancer, 2006,107 : 1562- 1569.
  • 6Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in ad vanced hepatocellular carcinoma. N Engl J Med, 2008, 359: 378- 390.
  • 7Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 2004, 64:7099-7109.
  • 8Tang ZY, Ye SL, Liu YK, et al. A decade's studies on metas tasis of hepatocellular carcinoma. J Cancer Res Clin Oncol, 2004,130 : 187-196.
  • 9丁永康.肝癌的流行因素和预防[J].临床实践医学杂志,2009,8(2):118-120.
  • 10Lovet JM,Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma[J]. Semin Liver Dis,2005,25(2) :181-200.

共引文献57

同被引文献197

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部